Showing results (601-610 of 655) with videos related to
Sort By:
Pageof 66
Lancet (London, England)|June 5, 2026
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)Brendon L Neuen, Hiddo J L Heerspink, Vlado Perkovic, et al.JACC. Heart Failure|June 12, 2025
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART AnalysisJohn W Ostrominski, Gerasimos Filippatos, Brian L Claggett, et al.Diabetes Care|February 28, 2025
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney DiseaseJohn W Ostrominski, Brian L Claggett, Zi Michael Miao, et al.Nature Microbiology|July 31, 2025
Polypeptides synthesized by common bacteria in the human gut improve rodent metabolismYong Fan, Liwei Lyu, Ruben Vazquez-Uribe, et al.Journal of the American College of Cardiology|June 3, 2026
Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART AnalysisAlberto Foà, Maria A Pabon, Gerasimos Filippatos, et al.Journal of the American College of Cardiology|September 2, 2025
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global TrialsJohn W Ostrominski, Josephine Harrington, Brian L Claggett, et al.Diabetologia|December 15, 2018
A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuriaTarunveer S Ahluwalia, Christina-Alexandra Schulz, Johannes Waage, et al.The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.Cardiovascular Diabetology|April 9, 2022
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomesOliver Schnell, Tadej Battelino, Richard Bergenstal, et al.NEJM Evidence|October 28, 2025
Cardiac Effects of Dapagliflozin in People with Chronic Kidney DiseaseKatja Vu Bartholdy, Niklas Dyrby Johansen, Kristoffer Grundtvig Skaarup, et al.Pageof 66